Y-mAbs Therapeutics (YMAB) Tops Q1 EPS by 8c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q1 EPS of ($0.64), $0.08 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.9 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral
• JPMorgan Downgrades Woolworths Holdings Ltd (WHL:SJ) to Underweight